Buyside analysts
- Size the catalyst against what the market priced
- See which precedents agree, and which one does not apply
- Hand over a shortlist with the disagreement already marked
The catalyst, explained
A company, its lead asset, and how the stock moved.
Price, peers, and the announcements that did not move it.
Who it's for
When price action and the evidence split
It is the step where a biotech position has to be defended.
Portfolio managers
- Read the asset, the peers, and the event in one place
- See what the market priced and what the evidence says
- Decide the position before the readout is consensus
One ticker
The foundation, the watchlist, the precedent
The scientific case for the drug: mechanism, endpoints, and the evidence behind it.
An agent that analyses investment horizons and suggests strategic and tactical repositioning.
What a hit and a miss did to this ticker, last time.
The point
Why Biosentinel?
Early work on a biotech ticker is interpretation. When the market reaction and the evidence split, Biosentinel rebuilds the chain before that week starts.